MEDINDIA
English
हिन्दी
Español
français
中文
Email
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Eribulin.
Amiodarone
Eribulin may increase the QTc-prolonging activities of Amiodarone.
Anagrelide
Eribulin may increase the QTc-prolonging activities of Anagrelide.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Eribulin.
Arsenic Trioxide
Eribulin may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Eribulin may increase the QTc-prolonging activities of Artemether.
Asenapine
Eribulin may increase the QTc-prolonging activities of Asenapine.
Azithromycin
Eribulin may increase the QTc-prolonging activities of Azithromycin.
Bedaquiline
Eribulin may increase the QTc-prolonging activities of Bedaquiline.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Eribulin.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Eribulin.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Eribulin.
Ceritinib
Eribulin may increase the QTc-prolonging activities of Ceritinib.
Chloroquine
Eribulin may increase the QTc-prolonging activities of Chloroquine.
Chlorpromazine
Eribulin may increase the QTc-prolonging activities of Chlorpromazine.
Ciprofloxacin
Eribulin may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Eribulin may increase the QTc-prolonging activities of Cisapride.
Citalopram
Eribulin may increase the QTc-prolonging activities of Citalopram.
Clarithromycin
Eribulin may increase the QTc-prolonging activities of Clarithromycin.
Clozapine
The risk or severity of adverse effects can be increased when Eribulin is combined with Clozapine.
Crizotinib
Eribulin may increase the QTc-prolonging activities of Crizotinib.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Eribulin.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Eribulin.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Eribulin.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Eribulin.
Digoxin
Digoxin may decrease the cardiotoxic activities of Eribulin.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Eribulin.
Disopyramide
Eribulin may increase the QTc-prolonging activities of Disopyramide.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Eribulin.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Eribulin.
Dofetilide
Eribulin may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Eribulin may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Eribulin may increase the QTc-prolonging activities of Domperidone.
Dronedarone
Eribulin may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Eribulin may increase the QTc-prolonging activities of Droperidol.
Eliglustat
Eribulin may increase the QTc-prolonging activities of Eliglustat.
Erythromycin
Eribulin may increase the QTc-prolonging activities of Erythromycin.
Escitalopram
Eribulin may increase the QTc-prolonging activities of Escitalopram.
Flecainide
Eribulin may increase the QTc-prolonging activities of Flecainide.
Fluoxetine
Eribulin may increase the QTc-prolonging activities of Fluoxetine.
Flupenthixol
Eribulin may increase the QTc-prolonging activities of Flupentixol.
Gadobenate
Eribulin may increase the QTc-prolonging activities of Gadobenic acid.
Gemifloxacin
Eribulin may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Eribulin may increase the QTc-prolonging activities of Gemifloxacin.
Goserelin
Eribulin may increase the QTc-prolonging activities of Goserelin.
Granisetron
Eribulin may increase the QTc-prolonging activities of Granisetron.
Haloperidol
Eribulin may increase the QTc-prolonging activities of Haloperidol.
Ibutilide
Eribulin may increase the QTc-prolonging activities of Ibutilide.
Iloperidone
Eribulin may increase the QTc-prolonging activities of Iloperidone.
Lenvatinib
Eribulin may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Eribulin may increase the QTc-prolonging activities of Lenvatinib.
Leuprolide
Eribulin may increase the QTc-prolonging activities of Leuprolide.
Levofloxacin
Eribulin may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Eribulin may increase the QTc-prolonging activities of Levofloxacin.
Lipegfilgrastim
Eribulin may increase the myelosuppressive activities of Lipegfilgrastim.
Lopinavir
Eribulin may increase the QTc-prolonging activities of Lopinavir.
Lumefantrine
Eribulin may increase the QTc-prolonging activities of Lumefantrine.
Methadone
Eribulin may increase the QTc-prolonging activities of Methadone.
Mifepristone
Mifepristone may increase the QTc-prolonging activities of Eribulin.
Moxifloxacin
Eribulin may increase the QTc-prolonging activities of Moxifloxacin.
Nilotinib
Eribulin may increase the QTc-prolonging activities of Nilotinib.
Ofloxacin
Eribulin may increase the QTc-prolonging activities of Ofloxacin.
Ondansetron
Eribulin may increase the QTc-prolonging activities of Ondansetron.
Ouabain
Ouabain may decrease the cardiotoxic activities of Eribulin.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Eribulin.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Eribulin.
Paliperidone
Eribulin may increase the QTc-prolonging activities of Paliperidone.
Panobinostat
Eribulin may increase the QTc-prolonging activities of Panobinostat.
Pazopanib
Eribulin may increase the QTc-prolonging activities of Pazopanib.
Pentamidine
Eribulin may increase the QTc-prolonging activities of Pentamidine.
Perflutren
Eribulin may increase the QTc-prolonging activities of Perflutren.
Pimozide
Eribulin may increase the QTc-prolonging activities of Pimozide.
Primaquine
Eribulin may increase the QTc-prolonging activities of Primaquine.
Procainamide
Eribulin may increase the QTc-prolonging activities of Procainamide.
Promazine
Eribulin may increase the QTc-prolonging activities of Promazine.
Propafenone
Eribulin may increase the QTc-prolonging activities of Propafenone.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Eribulin.
Quetiapine
Eribulin may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Eribulin may increase the QTc-prolonging activities of Quetiapine.
Quinidine
Eribulin may increase the QTc-prolonging activities of Quinidine.
Quinine
Eribulin may increase the QTc-prolonging activities of Quinine.
Saquinavir
Eribulin may increase the QTc-prolonging activities of Saquinavir.
Saquinavir Mesylate
Eribulin may increase the QTc-prolonging activities of Saquinavir.
Sotalol
Eribulin may increase the QTc-prolonging activities of Sotalol.
Sulfisoxazole
Eribulin may increase the QTc-prolonging activities of Sulfisoxazole.
Telavancin
Eribulin may increase the QTc-prolonging activities of Telavancin.
Telithromycin
Eribulin may increase the QTc-prolonging activities of Telithromycin.
Tetrabenazine
Eribulin may increase the QTc-prolonging activities of Tetrabenazine.
Thioridazine
Eribulin may increase the QTc-prolonging activities of Thioridazine.
Toremifene
Eribulin may increase the QTc-prolonging activities of Toremifene.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Eribulin.
Vandetanib
Eribulin may increase the QTc-prolonging activities of Vandetanib.
Vemurafenib
Eribulin may increase the QTc-prolonging activities of Vemurafenib.
Ziprasidone
Eribulin may increase the QTc-prolonging activities of Ziprasidone.
Zuclopenthixol
Eribulin may increase the QTc-prolonging activities of Zuclopenthixol.
